Gilead Sciences (GILD) Closes $7.8B Arcellx Buyout — What Investors Need to Know

Key Takeaways

Table of Contents

On April 28, 2026, Gilead finalized its $7.8 billion purchase of Arcellx, securing complete ownership of anito-cel, a CAR T-cell treatment for multiple myeloma.
The stock is revisiting breakout levels from an 11-year cup base formation around $123.47, with one market watcher projecting a climb to $173 by December — representing potential upside of 35%.
Shares have dropped 8% during April but remain up 22% year-over-year, currently hovering near $128.
Technical indicators show GILD’s RSI at 27, marking its most oversold reading in over 12 months, while the 200-day moving average provides nearby support.
While the acquisition will reduce both GAAP and non-GAAP earnings per share by $5.57–$5.67 in 2026, projections indicate positive contributions starting in 2028, contingent on regulatory clearance.

Gilead Sciences finalized its Arcellx takeover on April 28, offering $115 cash per share alongside a $5 contingent value right. The transaction valued Arcellx’s equity at roughly $7.8 billion at closing.

Gilead Sciences, Inc., GILD

This acquisition grants Gilead complete ownership of anitocabtagene autoleucel (anito-cel), an experimental BCMA-targeted CAR T-cell treatment designed for multiple myeloma patients. The two companies had previously partnered through Kite, Gilead’s cellular therapy division.

By acquiring Arcellx completely, Gilead removes future royalty commitments, milestone payments, and profit-sharing arrangements. This streamlined structure enables more agile decision-making regarding development timelines and market launch strategies.

The contingent $5 CVR payment per share triggers only if anito-cel generates cumulative worldwide sales reaching $6 billion between its launch date and December 31, 2029. While challenging, this threshold demonstrates Gilead’s optimism about the therapy’s revenue potential.

Cindy Perettie, who leads Gilead’s Kite division, emphasized the priority is now “executing with speed and discipline” while preparing anito-cel for patient access. Arcellx’s personnel and its proprietary D-Domain BCMA binder platform will merge into Kite’s existing manufacturing and compliance frameworks.

Financially, the deal will decrease Gilead’s 2026 diluted earnings per share by $5.57 to $5.67 under both GAAP and adjusted metrics. When excluding acquired in-process research and development costs, modest dilution is anticipated through 2027, with earnings accretion expected beginning in 2028 — assuming anito-cel receives FDA authorization.

Arcellx shares will be removed from Nasdaq Global Select Market trading following the merger’s conclusion.

Chart Analysis

From a technical perspective, GILD finds itself at a noteworthy juncture. Shares are retesting a breakout from an 11-year cup-shaped base pattern with a pivot point at $123.47 — a formation originating from bearish candlestick patterns observed during June and July 2015.

Extended consolidation patterns historically demonstrate higher breakout success probabilities, making this current retest particularly significant. The stock’s Relative Strength Index has fallen to 27, its lowest reading in at least twelve months, indicating deeply oversold territory. The 200-day simple moving average lies close by and previously provided support during May and October last year.

GILD has posted losses in eight of the previous ten weeks, including an 8% decline through April. Notably, both March and April’s downward movements occurred on lighter-than-average trading volume, which technical traders often interpret as a positive divergence.

Biotech Sector Overview

The SPDR S&P Biotech ETF has climbed 9% in 2026, outperforming the broader healthcare sector’s 7% decline — currently the weakest performer among all eleven major S&P sectors. Meanwhile, the iShares Biotechnology ETF, which holds Gilead as its top position at nearly 8% weighting, has delivered less than 1% returns year-to-date.

GILD shares have advanced 4% since January and 22% over the trailing twelve months despite recent weakness. One chart analyst has established a $173 price objective for year-end, suggesting 35% appreciation from the current $128 level. The bullish scenario remains intact provided shares maintain support above $118.

Gilead completed its tender offer for Arcellx on April 28, with tendered shares accounting for approximately 77.2% of Arcellx’s total outstanding equity.

✨ Limited Time Offer